Cells (Oct 2020)

Structural Basis of Inhibition of the Pioneer Transcription Factor NF-Y by Suramin

  • Valentina Nardone,
  • Antonio Chaves-Sanjuan,
  • Michela Lapi,
  • Cristina Airoldi,
  • Andrea Saponaro,
  • Sebastiano Pasqualato,
  • Diletta Dolfini,
  • Carlo Camilloni,
  • Andrea Bernardini,
  • Nerina Gnesutta,
  • Roberto Mantovani,
  • Marco Nardini

DOI
https://doi.org/10.3390/cells9112370
Journal volume & issue
Vol. 9, no. 11
p. 2370

Abstract

Read online

NF-Y is a transcription factor (TF) comprising three subunits (NF-YA, NF-YB, NF-YC) that binds with high specificity to the CCAAT sequence, a widespread regulatory element in gene promoters of prosurvival, cell-cycle-promoting, and metabolic genes. Tumor cells undergo “metabolic rewiring” through overexpression of genes involved in such pathways, many of which are under NF-Y control. In addition, NF-YA appears to be overexpressed in many tumor types. Thus, limiting NF-Y activity may represent a desirable anti-cancer strategy, which is an ongoing field of research. With virtual-screening docking simulations on a library of pharmacologically active compounds, we identified suramin as a potential NF-Y inhibitor. We focused on suramin given its high water-solubility that is an important factor for in vitro testing, since NF-Y is sensitive to DMSO. By electrophoretic mobility shift assays (EMSA), isothermal titration calorimetry (ITC), STD NMR, X-ray crystallography, and molecular dynamics (MD) simulations, we showed that suramin binds to the histone fold domains (HFDs) of NF-Y, preventing DNA-binding. Our analyses, provide atomic-level detail on the interaction between suramin and NF-Y and reveal a region of the protein, nearby the suramin-binding site and poorly conserved in other HFD-containing TFs, that may represent a promising starting point for rational design of more specific and potent inhibitors with potential therapeutic applications.

Keywords